Quote | Belite Bio Inc (NASDAQ:BLTE)
Last: | $48.12 |
---|---|
Change Percent: | 1.0% |
Open: | $49.6 |
Close: | $48.12 |
High: | $49.694 |
Low: | $47.82 |
Volume: | 46,723 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
News | Belite Bio Inc (NASDAQ:BLTE)
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata...
Message Board Posts | Belite Bio Inc (NASDAQ:BLTE)
Subject | By | Source | When |
---|---|---|---|
Found an interesting article | conix | investorshub | 06/21/2023 7:36:39 AM |
$BLTE good read | conix | investorshub | 06/19/2023 4:42:31 AM |
$BLTE Price now up | conix | investorshub | 06/15/2023 11:39:25 AM |
Short Interest for $BLTE--Up 30% | conix | investorshub | 09/18/2022 4:26:19 PM |
$BLTE News | conix | investorshub | 08/23/2022 4:13:07 PM |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...